Since absorption of nebulized and subcutaneous terbutaline may be delayed or decreased during episodes of severe asthma, a preliminary trial of intravenous terbutaline was instituted in five adult patients with status asthmaticus. The terbutaline was administered as a bolus followed by a continuous infusion of 0.1-0.4 μg/kg/min. Although three patients may have received some improvement, the impact of intravenous terbutaline could not be distinguished from other concomitant therapy. All patients experienced tolerable adverse reactions. Further research to evaluate higher doses administered early in the hospital course and to determine receptor sensitivity needs to be conducted.
|Original language||English (US)|
|Number of pages||6|
|Journal||Annals of Allergy|
|Issue number||2 II|
|State||Published - Jan 1 1990|